voclosporin (Lupkynistm)
Jump to navigation
Jump to search
Indications
- for use in combination with an immunosuppressive therapy regimen to treat active lupus nephritis in adult[1]
Adverse effects
- infections (10.1% vs 11.2%)
- urinary tract infection (>3%)
- other > 3%
- abdominal pain, dyspepsia, diarrhea
- mouth ulceration
- decreased appetite
- fatigue
- tremor
- alopecia
Mechanism of action
More general terms
References
- ↑ 1.0 1.1 FDA Approves Aurinia Pharmaceuticals' LUPKYNIS <TM> (voclosporin) for Adult Patients with Active Lupus Nephritis businesswire. Jan 22, 2021. https://www.businesswire.com/news/home/20210122005501/en/FDA-Approves-Aurinia-Pharmaceuticals%E2%80%99-LUPKYNIS%E2%84%A2-voclosporin-for-Adult-Patients-with-Active-Lupus-Nephritis
Splete H FDA Approves Voclosporin for Lupus Nephritis Medscape - Jan 27, 2021. https://www.medscape.com/viewarticle/944794